LT3581654T - Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnr - Google Patents
Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnrInfo
- Publication number
- LT3581654T LT3581654T LTEP19182616.3T LT19182616T LT3581654T LT 3581654 T LT3581654 T LT 3581654T LT 19182616 T LT19182616 T LT 19182616T LT 3581654 T LT3581654 T LT 3581654T
- Authority
- LT
- Lithuania
- Prior art keywords
- hao1
- compositions
- methods
- specific inhibition
- glycolate oxidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361921181P | 2013-12-27 | 2013-12-27 | |
| US201461937838P | 2014-02-10 | 2014-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3581654T true LT3581654T (lt) | 2021-06-25 |
Family
ID=53479713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP19182616.3T LT3581654T (lt) | 2013-12-27 | 2014-12-26 | Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnr |
| LTPA2021008C LTC3581654I2 (enExample) | 2013-12-27 | 2021-09-01 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTPA2021008C LTC3581654I2 (enExample) | 2013-12-27 | 2021-09-01 |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US9701966B2 (enExample) |
| EP (3) | EP3892727A1 (enExample) |
| JP (2) | JP6886818B2 (enExample) |
| AU (2) | AU2014369850B2 (enExample) |
| CA (1) | CA2935220A1 (enExample) |
| CY (2) | CY1124203T1 (enExample) |
| DK (2) | DK3087184T3 (enExample) |
| ES (2) | ES2875558T3 (enExample) |
| FI (1) | FIC20210025I1 (enExample) |
| FR (1) | FR21C1044I2 (enExample) |
| HR (1) | HRP20210612T1 (enExample) |
| HU (2) | HUE055470T2 (enExample) |
| LT (2) | LT3581654T (enExample) |
| LU (1) | LUC00218I2 (enExample) |
| NO (1) | NO2021038I1 (enExample) |
| PL (1) | PL3581654T3 (enExample) |
| PT (1) | PT3581654T (enExample) |
| RS (1) | RS61892B1 (enExample) |
| SI (1) | SI3581654T1 (enExample) |
| SM (1) | SMT202100325T1 (enExample) |
| WO (1) | WO2015100436A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| RS61892B1 (sr) | 2013-12-27 | 2021-06-30 | Dicerna Pharmaceuticals Inc | Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk |
| TWI755351B (zh) * | 2014-10-10 | 2022-02-21 | 美商艾爾妮蘭製藥公司 | 用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法 |
| WO2016205323A1 (en) * | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| CA3036620A1 (en) * | 2016-10-05 | 2018-04-12 | Syngenta Participations Ag | Methods of preserving the biological activity of ribonucleic acids |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| AU2018301829B2 (en) | 2017-07-13 | 2024-08-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression |
| AU2019313348A1 (en) * | 2018-07-31 | 2021-03-04 | Intellia Therapeutics, Inc. | Compositions and methods for hydroxyacid oxidase 1 (HAO1) gene editing for treating primary hyperoxaluria type 1 (PH1) |
| EP3898661A1 (en) * | 2018-12-21 | 2021-10-27 | Precision BioSciences, Inc. | Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria |
| WO2021086874A1 (en) | 2019-11-01 | 2021-05-06 | GyanRx Sciences, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4153752A4 (en) * | 2020-05-22 | 2025-10-01 | Harvard College | INTERFERON-INDUCING OLIGONUCLEOTIDE DUPLEXES AND METHODS OF USE |
| WO2022104062A1 (en) | 2020-11-12 | 2022-05-19 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
| EP4043018A1 (en) | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
| CA3222159A1 (en) * | 2021-06-04 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof |
| JP2024528659A (ja) * | 2021-07-19 | 2024-07-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US513207A (en) | 1894-01-23 | Rail-brake | ||
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| JPH09502092A (ja) | 1993-09-02 | 1997-03-04 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 非ヌクレオチドを含有する酵素性核酸 |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| US7678897B2 (en) * | 2002-02-20 | 2010-03-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9879266B2 (en) * | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| JP4644619B2 (ja) | 2006-03-27 | 2011-03-02 | 富士通株式会社 | 基地局装置、端末および帯域制御方法 |
| DE102007021853A1 (de) | 2007-05-10 | 2008-11-13 | Norma Germany Gmbh | Steckkupplung und Stutzen für eine Steckkupplung |
| US20110288147A1 (en) | 2008-09-22 | 2011-11-24 | Bob Dale Brown | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop |
| CN101752443B (zh) | 2008-12-08 | 2012-06-20 | 鸿富锦精密工业（深圳）有限公司 | 光伏电池 |
| CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| US8632982B2 (en) * | 2009-05-21 | 2014-01-21 | Institute For Systems Biology | Biomarkers for liver injury |
| WO2013075035A1 (en) | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| RS61892B1 (sr) | 2013-12-27 | 2021-06-30 | Dicerna Pharmaceuticals Inc | Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk |
| TWI755351B (zh) * | 2014-10-10 | 2022-02-21 | 美商艾爾妮蘭製藥公司 | 用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法 |
-
2014
- 2014-12-26 RS RS20210652A patent/RS61892B1/sr unknown
- 2014-12-26 ES ES19182616T patent/ES2875558T3/es active Active
- 2014-12-26 EP EP21163279.9A patent/EP3892727A1/en not_active Withdrawn
- 2014-12-26 ES ES14874374T patent/ES2749855T3/es active Active
- 2014-12-26 HU HUE19182616A patent/HUE055470T2/hu unknown
- 2014-12-26 EP EP19182616.3A patent/EP3581654B1/en active Active
- 2014-12-26 SI SI201431812T patent/SI3581654T1/sl unknown
- 2014-12-26 SM SM20210325T patent/SMT202100325T1/it unknown
- 2014-12-26 US US14/583,200 patent/US9701966B2/en active Active
- 2014-12-26 WO PCT/US2014/072410 patent/WO2015100436A1/en not_active Ceased
- 2014-12-26 JP JP2016543143A patent/JP6886818B2/ja active Active
- 2014-12-26 PT PT191826163T patent/PT3581654T/pt unknown
- 2014-12-26 AU AU2014369850A patent/AU2014369850B2/en active Active
- 2014-12-26 LT LTEP19182616.3T patent/LT3581654T/lt unknown
- 2014-12-26 DK DK14874374.3T patent/DK3087184T3/da active
- 2014-12-26 EP EP14874374.3A patent/EP3087184B1/en active Active
- 2014-12-26 CA CA2935220A patent/CA2935220A1/en active Pending
- 2014-12-26 PL PL19182616T patent/PL3581654T3/pl unknown
- 2014-12-26 DK DK19182616.3T patent/DK3581654T3/da active
-
2017
- 2017-06-07 US US15/616,254 patent/US9828606B2/en active Active
- 2017-10-25 US US15/793,441 patent/US10435692B2/en active Active
-
2019
- 2019-03-08 US US16/297,354 patent/US10487330B2/en active Active
- 2019-03-08 US US16/297,316 patent/US10465195B2/en active Active
- 2019-08-20 US US16/545,149 patent/US11060093B2/en active Active
- 2019-11-08 JP JP2019202937A patent/JP7109416B2/ja active Active
-
2021
- 2021-01-25 US US17/157,803 patent/US11873493B2/en active Active
- 2021-03-29 AU AU2021201953A patent/AU2021201953A1/en not_active Abandoned
- 2021-04-16 HR HRP20210612TT patent/HRP20210612T1/hr unknown
- 2021-05-28 CY CY20211100465T patent/CY1124203T1/el unknown
- 2021-08-18 LU LU00218C patent/LUC00218I2/fr unknown
- 2021-08-25 FI FIC20210025C patent/FIC20210025I1/fi unknown
- 2021-08-26 CY CY2021022C patent/CY2021022I1/el unknown
- 2021-09-01 LT LTPA2021008C patent/LTC3581654I2/lt unknown
- 2021-09-16 NO NO2021038C patent/NO2021038I1/no unknown
- 2021-09-20 FR FR21C1044C patent/FR21C1044I2/fr active Active
- 2021-09-28 HU HUS2100041C patent/HUS2100041I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3581654T (lt) | Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnr | |
| CY2021029I2 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| IL269461B (en) | Cytidine-5-carboxamide modified nucleotide preparations and related methods | |
| LT3527263T (lt) | Bipirazolo dariniai, kaip jak inhibitoriai | |
| DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
| DK2699553T3 (da) | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK3234134T3 (da) | Målrettet rna-redigering | |
| LT3702351T (lt) | Kompozicijos, apimančios mek inhibitorių | |
| DK3074027T3 (da) | Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf | |
| BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
| SG11201509933QA (en) | Compositions and methods for selectively etching titanium nitride | |
| LT3108009T (lt) | Būdai ir kompozicijos, skirti dnr profiliavimui | |
| SG10201801575YA (en) | Compositions and methods for selectively etching titanium nitride | |
| SG11201507014RA (en) | Compositions and methods for selectively etching titanium nitride | |
| PT3035936T (pt) | Entidades quimicas, composições e métodos particulares | |
| LT2970890T (lt) | Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui | |
| CL2015003479A1 (es) | Métodos y composiciones de fermentación bacterial. | |
| IL245839B (en) | Inhibitors of rna polymerase i and use of preparations containing them for treatment | |
| LT3076971T (lt) | Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas | |
| EP2982331A4 (en) | Treatment tool | |
| EP3012292A4 (en) | PROCESSING AGENTS AND COMPOSITION | |
| EP3046554A4 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| PL3250042T3 (pl) | Kompozycja, sposób, zastosowanie i wyrób | |
| LT3233862T (lt) | Imidazopiridazino dariniai, kaip pi3kbeta slopikliai | |
| DK3003298T3 (da) | Antifibrogene forbindelser, fremgangsmåder og anvendelser deraf |